Date: May 28, 2026
Regulatory Compliance Disclosure
MedPlus Health Services Limited informs that its subsidiary, Optival Health Solutions Private Limited, has received three drug license suspension orders from state drug control authorities.
Details of Regulatory Actions
First Suspension Order:
- Authority: Assistant Director, Drugs Control Administration, Shameerpet-Mechel Malkajgiri Dist, Telangana
- Nature of Action: Suspension of Drug License for three days
- Store Location: Maruthi Nagar Kothapet Village, Telangana
- Date of Order Receipt: May 27, 2026
- Violation Cited: Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945
- Financial Impact: Potential Revenue Loss of ₹1.35 lakhs
Second Suspension Order:
- Authority: Assistant Director, Drugs Control Administration, Bangalore Rural Circle, Devanahalli, Karnataka
- Nature of Action: Suspension of Drug License for two days
- Store Location: Channappa Layout Nelamangala, Karnataka
- Financial Impact: Potential Revenue Loss of ₹1.49 lakhs
Third Suspension Order:
- Authority: Assistant Director, Drugs Control Administration, Bangalore circle-5, Bangalore, Karnataka
- Nature of Action: Suspension of Drug License for one day
- Store Location: Binny Mill Road Ganganagar, Karnataka
- Financial Impact: Potential Revenue Loss of ₹0.65 lakhs
Total Financial Impact
The company estimates the cumulative potential revenue loss across all three store suspensions to be ₹3.49 lakhs.
Disclosure Compliance
The disclosure is made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.
The information will be available on the company's website (www.medplusindia.com) and on the websites of BSE Limited (www.bseindia.com) and National Stock Exchange of India Ltd. (www.nseindia.com).